Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Reconstruction of pathway modification induced by nicotinamide using multi-omic network analyses in triple negative breast cancer.

Kim JY, Lee H, Woo J, Yue W, Kim K, Choi S, Jang JJ, Kim Y, Park IA, Han D, Ryu HS.

Sci Rep. 2017 Jun 14;7(1):3466. doi: 10.1038/s41598-017-03322-7.

2.

Safety of endoscopy in cancer patients on antiangiogenic agents: A retrospective multicenter outcomes study.

Kachaamy T, Gupta D, Edwin P, Vashi P.

PLoS One. 2017 May 4;12(5):e0176899. doi: 10.1371/journal.pone.0176899. eCollection 2017.

3.

Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.

Bear HD, Wan W, Robidoux A, Rubin P, Limentani S, White RL Jr, Granfortuna J, Hopkins JO, Oldham D, Rodriguez A, Sing AP.

J Surg Oncol. 2017 Jun;115(8):917-923. doi: 10.1002/jso.24610. Epub 2017 Apr 13.

PMID:
28407247
4.

Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.

Vahdat LT, Layman R, Yardley DA, Gradishar W, Salkeni MA, Joy AA, Garcia AA, Ward P, Khatcheressian J, Sparano J, Rodriguez G, Tang S, Gao L, Dalal RP, Kauh J, Miller K.

Oncologist. 2017 Mar;22(3):245-254. doi: 10.1634/theoncologist.2016-0265. Epub 2017 Feb 20.

PMID:
28220020
5.

Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.

Kiss B, Wyatt AW, Douglas J, Skuginna V, Mo F, Anderson S, Rotzer D, Fleischmann A, Genitsch V, Hayashi T, Neuenschwander M, Buerki C, Davicioni E, Collins C, Thalmann GN, Black PC, Seiler R.

Sci Rep. 2017 Feb 16;7:42713. doi: 10.1038/srep42713.

6.

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.

Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, Stevenson L, Grabsch HI, Alderson D, Crosby T, Griffin SM, Mansoor W, Coxon FY, Falk SJ, Darby S, Sumpter KA, Blazeby JM, Langley RE.

Lancet Oncol. 2017 Mar;18(3):357-370. doi: 10.1016/S1470-2045(17)30043-8. Epub 2017 Feb 3.

7.

Angiopoietin pathway gene expression associated with poor breast cancer survival.

Ramanathan R, Olex AL, Dozmorov M, Bear HD, Fernandez LJ, Takabe K.

Breast Cancer Res Treat. 2017 Feb;162(1):191-198. doi: 10.1007/s10549-017-4102-2. Epub 2017 Jan 6.

PMID:
28062977
8.

Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period.

Choi M, Park YH, Ahn JS, Im YH, Nam SJ, Cho SY, Cho EY.

J Pathol Transl Med. 2017 Jan;51(1):69-78. doi: 10.4132/jptm.2016.10.05. Epub 2016 Dec 25.

9.

Tumor-targeting adenovirus OBP-401 inhibits primary and metastatic tumor growth of triple-negative breast cancer in orthotopic nude-mouse models.

Yano S, Takehara K, Kishimoto H, Tazawa H, Urata Y, Kagawa S, Bouvet M, Fujiwara T, Hoffman RM.

Oncotarget. 2016 Dec 20;7(51):85273-85282. doi: 10.18632/oncotarget.13296.

10.

Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer.

Wu FT, Paez-Ribes M, Xu P, Man S, Bogdanovic E, Thurston G, Kerbel RS.

Sci Rep. 2016 Nov 14;6:36694. doi: 10.1038/srep36694.

11.

Current advances in biomarkers for targeted therapy in triple-negative breast cancer.

Fleisher B, Clarke C, Ait-Oudhia S.

Breast Cancer (Dove Med Press). 2016 Oct 6;8:183-197. eCollection 2016. Review.

12.

Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.

Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GL, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK.

JCI Insight. 2016 Oct 20;1(17):e87754.

13.

Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer.

Ribatti D, Nico B, Ruggieri S, Tamma R, Simone G, Mangia A.

Transl Oncol. 2016 Oct;9(5):453-457. doi: 10.1016/j.tranon.2016.07.002. Review.

14.

Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

Jung YY, Hyun CL, Jin MS, Park IA, Chung YR, Shim B, Lee KH, Ryu HS.

J Breast Cancer. 2016 Sep;19(3):261-267. Epub 2016 Sep 23.

15.

Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer.

Wong AL, Sundar R, Wang TT, Ng TC, Zhang B, Tan SH, Soh TI, Pang AS, Tan CS, Ow SG, Wang L, Mogro J, Ho J, Jeyasekharan AD, Huang Y, Thng CH, Chan CW, Hartman M, Iau P, Buhari SA, Goh BC, Lee SC.

Oncotarget. 2016 Sep 27;7(39):64089-64099. doi: 10.18632/oncotarget.11596.

16.

Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment.

Mehta S, Hughes NP, Li S, Jubb A, Adams R, Lord S, Koumakis L, van Stiphout R, Padhani A, Makris A, Buffa FM, Harris AL.

EBioMedicine. 2016 Aug;10:109-16. doi: 10.1016/j.ebiom.2016.07.017. Epub 2016 Jul 16.

17.

Large intergenic non-coding RNA-ROR reverses gemcitabine-induced autophagy and apoptosis in breast cancer cells.

Chen YM, Liu Y, Wei HY, Lv KZ, Fu PF.

Oncotarget. 2016 Sep 13;7(37):59604-59617. doi: 10.18632/oncotarget.10730.

18.

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN.

Breast Cancer Res Treat. 2016 Aug;158(3):485-95. doi: 10.1007/s10549-016-3889-6. Epub 2016 Jul 8.

19.

Surgical Outcomes for Mastectomy Patients Receiving Neoadjuvant Chemotherapy: A Propensity-Matched Analysis.

Bowen ME, Mone MC, Buys SS, Sheng X, Nelson EW.

Ann Surg. 2017 Mar;265(3):448-456. doi: 10.1097/SLA.0000000000001804.

20.

Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.

Schröder L, Rack B, Sommer H, Koch JG, Weissenbacher T, Janni W, Schneeweiss A, Rezai M, Lorenz R, Jäger B, Schramm A, Häberle L, Fasching PA, Friedl TW, Beckmann MW, Scholz C.

Geburtshilfe Frauenheilkd. 2016 May;76(5):542-550.

Supplemental Content

Support Center